Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 436 publications.

Broughton EI, Bektas M, Colosia A, Fernandez M, Kuper K, Al-Taie A, Kotb REM. Assessing the global economic burden of complicated urinary tract infections. Poster presented at the IDWeek 2024; October 18, 2024. Los Angeles, California.

La E, Sweeney C, Singer D, Davenport E, Calhoun S, Harmelink A. Factors associated with healthcare professionals' RSV older adult vaccination knowledge and practices during the first season of vaccine availability in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.

Layton JB, Muthuri S, Lindaas A, Lloyd PC, Richey MM, Gruber JF, Clarke TC, Kowarski LS, McKillop M, Fisher S, Lyu H, Cheng A, Bui CL, Duenas PF, Chen Y, Forshee RA, Anderson SA, Beers JB, Burrell T, Chillarige Y, Anthony MS, Shoaibi A. Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States. Presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Layton JB, Lindaas A, Muthuri S, Lloyd PC, Richey MM, Gruber JF, Clarke TC, Kowarski L, McKillop M, Fisher S, Lyu H, Cheng A, Bui C, Duenas PF, Chen Y, Beers JB, Forshee RA, Anderson SA, Burrell T, Chillarige Y, Anthony MS, Shoaibi A. Risk of cardiovascular adverse events after COVID-19 diagnosis in the United States. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Weibel D, De Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J, Marsal J, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Pala E, Poblador-Plou B, Gimeno-Miguel A, Santos-Mejias A, Marconi E, Barbieri E, Stona L, Lysen T, Roy D, Hyeraci G, Girardi A, Lupattelli A, Desalegn AA, Villalobos F, Bissacco CA, Kendrick K, Garg R, Rubino H, Sturkenboom MCJM, Arana A. Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Ahmadizar F, Fortuny J, Royo AC, Plana E, Weinrib R, Garcia Esteban R, Boric K, Yefimenko N, Haugh M, Carreras JJ, Urchueguia-Fornes A, Correcher E, van den Berg JM, Lysen T, Villalobos F, Bissacco CA, Newbern EC, Willame C, Praet N, Sturkenboom MCJM. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data sources: methods and results of the second study feasibility assessment. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Peetluk LS, Djibo DA, Layton JB, Deng J, Deshazo J, Richey MM, Ogilvie RP, Parambi RJ, Miller M, Song J, Tarazi W, Weatherby LB, Bell EJ, Anthony MS, McMahill-Walraven CN, Yang GW, Seeger JD, Amend KL. Considerations for negative control outcome analyses in vaccine effectiveness studies: post-hoc analyses from an adult vaccine effectiveness study conducted within the FDA BEST initiative. Presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Layton JB, Richey M, Lindaas A, Muthuri S, Lloyd PC, Gruber JF, Bui C, McKillop M, Kowarski L, Lyu H, Cheng A, Wan Z, Clarke TC, Kawai AT, Beers J, Forshee RA, Anderson SA, Burrell T, Chillarige Y, Anthony MS, Shoaibi A. Events on day zero of follow-up: considerations for cohort studies of adverse events after COVID-19 diagnosis. Presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Layton JB, Peetluk LS, Lloyd PC, Jiao Y, Djibo DA, Deng J, Gruber JF, Ogilvie RP, Parambi R, Miller M, Song J, Weatherby LB, Bell EJ, Lo AC, Hervol JR, Wernecke M, Cho S, Wong H-L, Clarke TC, Bui CL, Stone A, Tarazi W, Deshazo J, Forshee RA, Anderson SA, Seeger JD, Amend KL, MaMahill-Walraven CN, Chillarige Y, Yang GW, Anthony MS, Shoaibi A. Effectiveness over time of a complete primary series of the original, monovalent COVID-19 vaccines among adults aged 18-64 years in the United States. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Carrico J, Hicks KA, Wilson E, Panozzo CA, Ghaswalla P. The annual economic burden of respiratory syncytial virus in adults in the United States. J Infect Dis. 2024 Aug 16;230(2):e342-52. doi: 10.1093/infdis/jiad559

Singer D, Sweeney C, Stempniewicz N, Reynolds M, Garbinsky D, Poston S. Knowledge, attitudes, and practices regarding herpes zoster vaccination among specialists. Popul Health Manag. 2024 Aug;27(4):231-40. doi: 10.1089/pop.2023.0284

O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M. Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S109. doi: 10.1016/j.jval.2024.03.580

Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. The public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 24, 2024. Copenhagen, Germany.

Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Real-world impact of pneumococcal conjugate vaccines on invasive pneumococcal disease for serotypes missing prespecified efficacy threshold in immunogenicity trials. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.

Shah HA, Herrera-Restrepo O, Jutlla G, Grace M, Graham J, Khan SA, Begum S, Kocaata K. Market and non-market productivity losses associated with invasive meningococcal disease (IMD) in the United States (US). Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.

Shah HA, Herrera-Restrepo O, Jutlla G, Carrico J, Hicks K, Kuylen E, Begum S, Clements D, Burman C, Sohn WY, Kocaata Z. Public health impact of MENABCWY vaccination in adolescents and MENB vaccination in infants in the United States. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.

Golan Y, Amin AN, Wilson M, Nguyen D, Kvasz M. Clinical and economic outcomes of microbiome therapy for preventing recurrence in recurrent clostridioides difficile infection (Cdi) in the us: comparison of fecal microbiota spores, live-brpk (formerly Ser-109) Vs fecal microbiota, live-Jslm. Poster presented at the Digestive Disease Week (DDW) 2024; May 18, 2024. Washington, DC.

La E, Sweeney C, Singer D, Davenport E, Calhoun S, Harmelink A. Evaluating healthcare professionals' knowledge, attitudes, and practices related to RSV disease and vaccination in older adults during the first season of RSV vaccine availability in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024.

George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w

Fernandez MM, Bektas M, Colosia A, Kuper K, Al-Taie A, Kotb R. Evidence gaps in the burden of complicated urinary tract infection (cUTI). Poster presented at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); April 27, 2024. Barcelona, Spain.

Ogilvie RP, Layton JB, Lloyd PC, Jiao Y, Djibo DA, Wong HL, Gruber JF, Parambi R, Deng J, Miller M, Song J, Weatherby LB, Peetluk L, Lo A, Matuska K, Wernecke M, Bui CL, Clarke TC, Cho S, Bell EJ, Yang G, Amend KL, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Anthony MS, Seeger JD, Shoaibi A. Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study. BMC Pediatr. 2024 Apr 26;24(1):276. doi: 10.1186/s12887-024-04756-5

Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-61. doi: 10.1007/s40273-023-01342-y

Viguerie A, Jacobson EU, Hicks KA, Bates L, Carrico J, Honeycutt A, Lyles C, Farnham PG. Assessing the impact of COVID-19 on HIV outcomes in the United States: a modeling study. Sex Transm Dis. 2024 Apr 1;51(4):299-304. doi: 10.1097/OLQ.0000000000001935

Golan Y, Amin A, Dubberke E, Wilson M, Nguyen D, Kvasz M. Budget impact analysis of VOWST™ oral spores (VOS, formerly SER-109) for prevention of recurrent clostridioides difficile infection (CDI) in the United States. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-2):S8.

Jacobson E, Viguerie A, Hicks K, Bates L, Honeycutt A, Carrico J, Farnham P. Strategies for eliminating racial/ethnic disparities in HIV incidence in the United States. Poster presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI); March 5, 2024. Denver, CO.

Ghaswalla P, Carrico J, Hicks KA. The annual economic burden of respiratory syncytial virus in adults in the United States. Presented at the 2024 Biomedical Advanced Research and Development Authority George Risi Memorial Journal Club; January 22, 2024.

Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Miller A, Toback S. Burden and impact of reactogenicity among adults receiving COVID-19 vaccines in the United States and Canada: results from a prospective observational study. Vaccines (Basel). 2024 Jan 13;12(1):83. doi: 10.3390/vaccines12010083

Paret K, Beyhaghi H, Herring WL, Mauskopf J, Shane LG, Rousculp WD. Going forward: potential impact of protein-based COVID-19 vaccination coverage on population outcomes and costs in the United States. Vaccines (Basel). 2024 Jan 12;12(1):74. doi: 10.3390/vaccines12010074

Layton JB, Peetluk L, Wong HL, Jiao Y, Djibo DA, Bui C, Lloyd PC, Gruber JF, Miller M, Ogilvie RP, Deng J, Parambi R, Song J, Weatherby LB, Lo AC, Matuska K, Wernecke M, Clarke TC, Cho S, Bell EJ, Seeger JD, Yang GW, Illei D, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Amend KL, Anthony M, Shoaibi A. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States. Vaccine-X. 2024 Jan;16:100447. doi: 10.1016/j.jvacx.2024.100447

Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc Stephane, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Dec 31;19(1):2167907. doi: 10.1080/21645515.2023.2167907

Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7

Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, Kurosky S, Gessner BD, Begier E. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023 Oct 20;10(11):ofad513. doi: 10.1093/ofid/ofad513

Khurana N, Hicks KA, Carrico J, Jacobson E, Farnham PG. Modeling the impact of injectable versus oral pre-exposure prophylaxis (PrEP) on HIV incidence and cost outcomes in the United States. Presentation to be given at the 2023 INFORMS Annual Meeting; October 16, 2023. Phoenix, AR.

Viguerie A, Jacobson EU, Hicks K, Bates L, Carrico J, Honeycutt A, Lyles C, Farnham PG. Assessing the impact of COVID-19 on HIV outcomes: a modeling study. Poster presented at the 2023 INFORMS Annual Meeting; October 16, 2023. Phoenix, AR.

Sinclair G, Sension M, Dretler A, Schneider S, Schubert C, Merrill D, Richardson D, Sherif B, Zografos L, Garris C. Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at the IDWeek 2023; October 13, 2023. Boston, MA.

Dandachi D, Cunningham D, Valenti W, Phoenix J, Nguyen K, Teichner P, Jean-Louis A, Reynolds M, Richardson D, Garris C. Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND). Poster presented at the IDWeek 2023; October 13, 2023. Boston, MA.

Kawai A, Fuller CC, Koram N, Agan A, Brown J, Burk J, Cai B, Daniels K, Fearrington J, Franklin JM, Hague C, Jamal-allial A, Johannes CB, Kempner M, Layton JB, Ma Q, Mai X, Mayer SE, Pawloski PA, Reynolds JS, Seals RM, Selvan M, Smith S, McMahill-Walraven CN, Gilsenan A, Platt R. Monitoring results from a postapproval safety study of Pfizer-BioNTech COVID-19 vaccine in the United States: vaccine utilization and incidence rates of myocarditis/pericarditis. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):182. doi: 10.1002/pds.5687

Ghaswalla P, Hitchens A, Candrilli SD, Carrico J, Hicks KA, Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018. Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.

Mayer SE, Fuller CC, Haynes K, Alam S, Brown JS, Daniels K, Hawrusik R, Horgan C, Jamal-allial A, Johannes CB, Kawai AT, Layton JB, Mai X, Marshall J, McMahill-Walraven CN, Reynolds JS, Seals R, Selvan M, Stemkowski S, Wang FT, Yost E, Gilsenan A, Platt R. Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 vaccines in four large US national insurers. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):186. doi: 10.1002/pds.5687

Weibel D, De Luise C, Elbers R, van den Bor R, Martin I, Cid-Royo A, Plana E, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Poblador-Plou B, Marconi E, Barbieri E, Stona L, Swart KMA, Roy D, Hyeraci G, Bartolini C, Lupattelli A, Villalobos F, Kendrick K, Garg R, Rubino H, Eijkemans R, Sturkenboom M, Arana A. Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):173-4. doi: 10.1002/pds.5687

Ahmadizar F, Fortuny J, Cid-Royo A, Plana E, Weinrib R, Garcia Esteban R, Boric K, Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687

Ogilvie RP, Layton JB, Wong HL, Jiao Y, Parambi RJ, Deng J, Miller M, Song J, Lloyd PC, Weatherby L, Peetluk LS, Bell EJ, Yang G, Amend KL, Kawai A, Lo AC, Matuska K, Wernecke M, Gruber JF, Clarke TC, Forshee RA, Anderson SA, Anthony MS, Chillarige Y, Seeger JD, Shoaibi A. Effectiveness of BNT162b2 COVID-19 vaccine in US children aged 5-17 years. Presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):78. doi: 10.1002/pds.5687

Layton JB, Peetluk LS, Wong H, Jiao Y, Ogilvie RP, Miller M, Glazier-Essalmi A, Parambi RJ, Song J, Garcia de Albeniz Martinez X, Lloyd PC, Lo A, Kawai A, Weatherby L, Bell EJ, Yang G, Amend KL, Gruber JF, Clarke TC, Forshee RA, Anderson SA, Wernecke M, Matuska K, Chillarige Y, Anthony M, Seeger JD, Shoaibi A. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States. Presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):608. doi: 10.1002/pds.5687

Knight C, Lin YC, Pelaez SM, Aragon JR. Cost analysis of Nuvaxovid™ COVID-19 vaccine as an annual booster dose for COVID-19 prevention in people older than 60 years in Spain. Poster presented at the XXII National Congress - XI International: Preventive medicine in society: a challenge for the future; September 20, 2023. Palma De Mallorca, Spain.

Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination in 50-59-year-olds: primary care knowledge and practices. Presented at the National Medical Association ( NMA) 2023 Annual Convention and Scientific Assembly; July 29, 2023. New Orleans, LA.

Osborne RH, Nelson L, Fehnel S, Williams N, Bender R, Ziemiecki R, Gymnopoulou E, De Paepe E, Vandendijck Y, Norcross L, Heijnen E, Ispas G, Comeaux C, Callendret B, Chan EKH, Scott JA. Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the respiratory infection intensity and impact questionnaire™ symptom scores. J Patient Rep Outcomes. 2023 Jun 1;7(1):51. doi: 10.1186/s41687-023-00593-9.

Chan EKH, Williams V, Romano C, Fehnel S, Slagle AF, Stoddard J, Sadoff J, Mayorga M, Lewis S, Yarr S, Ma J, Liu Y, Katz EG, McNulty P, van Dromme I, McQuarrie K. Psychometric evaluation of the symptoms of infection with coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial. J Patient Rep Outcomes. 2023 May 17;17(1):45. doi: 10.1186/s41687-023-00581-z

Sinclair G, Cunningham D, Gupta SK, Richardson D, Reynolds M, Nelson K, Puga A, Garris C. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at the 17th Annual ACTHIV 2023 Conference; May 4, 2023. Phoenix, AZ.

Sung A, Houghton K, Cornely OA, Neofytos D, Pagliuca A, Capparella MR, Aguado J, Jimenez M, Gheorghe M. Effectiveness, safety, and patterns of real-world isavuconazole use—a retrospective medical record review study of patients with invasive aspergillosis. Poster presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023; April 15, 2023. Copenhagen, Denmark.